<p>"They've done studies you know -- 60% of the time it works all the time."... "That doesn't make any sense."  We discuss the different types of antisense oligonucleotide (AON/ASO) technologies and how these can be used therapeutically for FSHD.</p>

"They've done studies you know -- 60% of the time it works all the time."... "That doesn't make any sense." We discuss the different types of antisense oligonucleotide (AON/ASO) technologies and how these can be used therapeutically for FSHD.

<p>"They've done studies you know -- 60% of the time it works all the time."... "That doesn't make any sense." &nbsp;We discuss the different types of antisense oligonucleotide (AON/ASO) technologies and how these can be used therapeutically for FSHD.</p>

Making sense of antisense oligonucleotide technology for FSHD

MyFSHD is about education and personal empowerment for the worldwide facioscapulohumeral muscular dystrophy (FSHD) community. Here we have discussions and commentary hosted by FSHD researcher Peter Jones, PhD, on many things of interest to the FSHD community. Learn about the science behind the different FSHD therapeutic approaches, FSHD pathology, family genetics and FSHD diagnostics. We will discuss upcoming clinical trials and what to look forward to. You will get to understand how you can be better prepared, become involved, and help contribute to defeating FSHD once and for all.

Share Making sense of antisense oligonucleotide technology for FSHD

Sign up to save your podcasts

Making sense of antisense oligonucleotide technology for FSHD

Making sense of antisense oligonucleotide technology for FSHD